Literature DB >> 18280530

Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.

Zachary C Hartman1, Daniel M Appledorn, Delila Serra, Oliver Glass, Todd B Mendelson, Timothy M Clay, Andrea Amalfitano.   

Abstract

Human Adenovirus Type 4 (HAdV-4) is responsible for epidemic outbreaks of Acute Respiratory Disease (especially in military recruits), and is known to cause significant morbidity with several reported cases of mortality. However, we do not understand why this serotype causes such high morbidity, and have little insight into the immunobiology of HAdV-4 infections. We have now developed a replication attenuated HAdV-4 vector system, and through it, demonstrate that HAdV-4 virions have enhanced infectivity of certain cell types and reveal aspects of the serotype-specific heightened innate immunogenicity of infectious HAdV-4 capsids both in vitro and in vivo. We further found that elements of this serotype-specific immunogenicity were dependent upon interactions with the complement system. These findings provide insights into the mechanisms possibly underlying the known morbidity accompanying wild-type HAdV-4 infections as well as highlight important considerations when considering development of alternative serotype vectors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18280530      PMCID: PMC2720025          DOI: 10.1016/j.virol.2008.01.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  62 in total

1.  Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications.

Authors:  B L Hodges; H K Evans; R S Everett; E Y Ding; D Serra; A Amalfitano
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. For the Adenovirus Surveillance Group.

Authors:  G C Gray; P R Goswami; M D Malasig; A W Hawksworth; D H Trump; M A Ryan; D P Schnurr
Journal:  Clin Infect Dis       Date:  2000-10-04       Impact factor: 9.079

Review 3.  Assays for monitoring cellular immune responses to active immunotherapy of cancer.

Authors:  T M Clay; A C Hobeika; P J Mosca; H K Lyerly; M A Morse
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

Review 4.  Intracellular trafficking of adenovirus: many means to many ends.

Authors:  Philip L Leopold; Ronald G Crystal
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

5.  Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1.

Authors:  Sean Diehl; J Anguita; A Hoffmeyer; T Zapton; J N Ihle; E Fikrig; M Rincón
Journal:  Immunity       Date:  2000-12       Impact factor: 31.745

6.  Replication-defective vector based on a chimpanzee adenovirus.

Authors:  S F Farina; G P Gao; Z Q Xiang; J J Rux; R M Burnett; M R Alvira; J Marsh; H C Ertl; J M Wilson
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production.

Authors:  Etiena Basner-Tschakarjan; Evelyn Gaffal; Meredith O'Keeffe; Damia Tormo; Andreas Limmer; Hermann Wagner; Hubertus Hochrein; Thomas Tüting
Journal:  J Gene Med       Date:  2006-11       Impact factor: 4.565

8.  Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons.

Authors:  Núria Morral; Wanda K O'Neal; Karen Rice; M Michelle Leland; Pedro A Piedra; Estuardo Aguilar-Córdova; K Dee Carey; Arthur L Beaudet; Claire Langston
Journal:  Hum Gene Ther       Date:  2002-01-01       Impact factor: 5.695

9.  Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004.

Authors:  Kevin L Russell; Anthony W Hawksworth; Margaret A K Ryan; Jennifer Strickler; Marina Irvine; Christian J Hansen; Gregory C Gray; Joel C Gaydos
Journal:  Vaccine       Date:  2006-01-24       Impact factor: 3.641

10.  Transmission dynamics and prospective environmental sampling of adenovirus in a military recruit setting.

Authors:  Kevin L Russell; Michael P Broderick; Suzanne E Franklin; Lawrence B Blyn; Nikki E Freed; Emily Moradi; David J Ecker; Peter E Kammerer; Miguel A Osuna; Adriana E Kajon; Cassandra B Morn; Margaret A K Ryan
Journal:  J Infect Dis       Date:  2006-08-25       Impact factor: 5.226

View more
  14 in total

1.  TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.

Authors:  D M Appledorn; S Patial; S Godbehere; N Parameswaran; A Amalfitano
Journal:  J Innate Immun       Date:  2009-03-04       Impact factor: 7.349

2.  Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

Authors:  Jie Tian; Zhili Xu; Jeffrey S Smith; Sean E Hofherr; Michael A Barry; Andrew P Byrnes
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

3.  CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy.

Authors:  Zenaido T Camacho; Mallory A Turner; Michael A Barry; Eric A Weaver
Journal:  Hum Gene Ther       Date:  2014-04-10       Impact factor: 5.695

4.  An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.

Authors:  Vincenzo Cerullo; Iulia Diaconu; Valentina Romano; Mari Hirvinen; Matteo Ugolini; Sophie Escutenaire; Sirkka-Liisa Holm; Anja Kipar; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

5.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

6.  A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Lois H Yoshida; Joseph Balint; Richard B Gayle; Andrea Amalfitano; Frank R Jones
Journal:  Immunol Lett       Date:  2008-12-13       Impact factor: 3.685

7.  Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.

Authors:  Eric A Weaver
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

8.  Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor.

Authors:  Zhili Xu; Jeffrey S Smith; Jie Tian; Andrew P Byrnes
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

9.  Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.

Authors:  Nathaniel J Schuldt; Yasser A Aldhamen; Sarah Godbehere-Roosa; Sergey S Seregin; Youssef A Kousa; Andrea Amalfitano
Journal:  Malar J       Date:  2012-06-21       Impact factor: 2.979

10.  Improving adenovirus based gene transfer: strategies to accomplish immune evasion.

Authors:  Sergey S Seregin; Andrea Amalfitano
Journal:  Viruses       Date:  2010-09-24       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.